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Background: Smoking is the leading cause of preventable death worldwide and has been shown to increase the
risk of multiple diseases including coronary artery disease (CAD). We sought to identify genes whose levels of
expression in whole blood correlate with self-reported smoking status.
Methods: Microarrays were used to identify gene expression changes in whole blood which correlated with
self-reported smoking status; a set of significant genes from the microarray analysis were validated by qRT-PCR in
an independent set of subjects. Stepwise forward logistic regression was performed using the qRT-PCR data to
create a predictive model whose performance was validated in an independent set of subjects and compared to
cotinine, a nicotine metabolite.
Results: Microarray analysis of whole blood RNA from 209 PREDICT subjects (41 current smokers, 4 quit ≤ 2
months, 64 quit > 2 months, 100 never smoked; NCT00500617) identified 4214 genes significantly correlated with
self-reported smoking status. qRT-PCR was performed on 1,071 PREDICT subjects across 256 microarray genes
significantly correlated with smoking or CAD. A five gene (CLDND1, LRRN3, MUC1, GOPC, LEF1) predictive model,
derived from the qRT-PCR data using stepwise forward logistic regression, had a cross-validated mean AUC of 0.93
(sensitivity=0.78; specificity=0.95), and was validated using 180 independent PREDICT subjects (AUC=0.82, CI 0.69-
0.94; sensitivity=0.63; specificity=0.94). Plasma from the 180 validation subjects was used to assess levels of cotinine;
a model using a threshold of 10 ng/ml cotinine resulted in an AUC of 0.89 (CI 0.81-0.97; sensitivity=0.81;
specificity=0.97; kappa with expression model = 0.53).
Conclusion: We have constructed and validated a whole blood gene expression score for the evaluation of
smoking status, demonstrating that clinical and environmental factors contributing to cardiovascular disease risk
can be assessed by gene expression.
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Tobacco use results in over 5 million deaths on an an-
nual basis and is the leading cause of preventable death
worldwide [1]. Exposure to tobacco smoke, by both ac-
tive and passive means, contributes to the increased risk
and development of numerous diseases, including
asthma, chronic obstructive pulmonary disease (COPD),
and several types of cancer [2]. A strong association also
exists between smoking and cardiovascular disease; up
to an 80% increased risk is observed for active smokers* Correspondence: jwingrove@cardiodx.com
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reproduction in any medium, provided the orand 30% for passive smokers [3]. Acute coronary syn-
dromes (ACS), stable angina, stroke, carotid and periph-
eral atherosclerosis are all increased in smokers [3].
Driving increased coronary disease risk are physiological
changes that occur in response to smoking, including
lipid oxidation/modification, vasomotor dysfunction, and
inflammation [3].
Changes in gene expression in peripheral blood cells
correlate with a number of systemic inflammatory and
immune-related disorders, including cardiovascular dis-
ease [4-8]. We have recently described the development
and validation of a peripheral blood gene expression
score (GES) for the assessment of the likelihood ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is derived from the expression levels of 23 genes as well
as age and sex; the genes are grouped into highly corre-
lated meta-genes which reflect both biological processes
and cell type prevalence [7,9]. The GES is related to the
current likelihood of obstructive CAD [7,9].
To better understand the physiological alterations
induced by smoking and their relation to the develop-
ment of CAD, we sought to identify changes in whole
blood gene expression that correlate with self-reported
smoking status. Herein we describe a set of genes
expressed in whole blood that are strongly affected by
smoking, and the development of a gene expression sig-
nature that is predictive of self-reported smoking status.
Methods
Patient selection and clinical methods
All patients were clinically referred for invasive angiog-
raphy; angiograms were performed based on local, insti-
tutional protocols. The microarray cohort of 210
subjects (110 case:control pairs, matched for age and
sex) and the qRT-PCR algorithm development and
validation cohorts (1,071, 180 respectively) were part
of PREDICT, a multi-center US study of patients re-
ferred for coronary angiography (www.clinicaltrials.gov,
NCT00500617). The institutional review boards at all
centers approved the study, and all patients gave written
informed consent. Quantitative coronary angiography
(QCA) was performed on all subjects as previously
described [9].
Blood collection and RNA purification
Whole blood samples were collected in PAXgeneW and
EDTA tubes prior to coronary angiography. PAXgeneW
tubes were processed according to the manufacturer’s
instructions, then frozen at −20°C. RNA was purified as
previously described, using the Agencourt RNAdvance
system [9] Plasma was isolated from EDTA tubes by
centrifugation at 1800 g for 10 min, followed by the re-
moval of the upper plasma layer and subsequent storage
at −80°C.
Microarray methods
Microarray samples were labeled and hybridized to 41K
Human Whole Genome Arrays (Agilent, PN #G4112A)
using the manufacturer’s protocol. Microarray data sets
have been deposited in GEO (GSE 20686). Agilent pro-
cessed signal values for array normalization were scaled
to a trimmed mean of 100 and then log2 transformed.
Standard array QC metrics (percent present, pair-wise
correlation, and signal intensity) were used for quality
assessment. Quantile normalization was subsequently
used to further normalize the data [10].Microarray analysis
To identify genes associated with smoking status, logistic
regression was performed, adjusting for age and sex.
Gene Set Enrichment Analysis (GSEA) was performed
with 4 different gene sets (curated gene sets = 3272 sets;
motif gene sets = 836 sets; computational gene sets =
881 sets; GO gene sets = 1454 sets) using 1000 permuta-
tions13; BINGO was used to assess enrichment of gene
ontology terms in the set of 4214 significant array genes;
a hypergeometric test was used to identify overrepre-
sented terms and results were corrected for multiple
testing using Benjamini & Hochberg False Discovery
Rate (FDR) [11]. Hierarchical clustering was performed
using Gene Cluster 3.0 using mean-centered expression
data in a complete linkage, correlation-based approach
[12]; clusters were visualized using Java Treeview [13].
The cell-type specificity of gene expression was evalu-
ated using whole-blood normalized expression values
derived from BioGPS [14].
Gene selection
Genes for qRT-PCR were selected from the microarray
data based on statistical significance, gene ontology
pathway analysis, and literature support.
qRT-PCR
Amplicon design and cDNA synthesis were performed
as previously described [7,8] qRT-PCR was performed
on the Biomark microfluidic platform (Fluidigm, South
San Francisco, CA). Prior to PCR, 2.5 ul of cDNA was
pre-amplified for 18 cycles using TaqManW PreAmp
Master Mix (Life Technologies, Carlsbad, CA) in a 10 ul
reaction volume. PCR reactions were run in duplicate on
Fluidigm 96X96 microfluidic gene expression chips, and
median Cp values used for analysis.
Statistical methods
Clinical/demographic factors were assessed for self-
reported smoking status association using univariate
logistic regression. Gene expression association with
smoking status was assessed by logistic regression (sex/
age adjusted). All statistical methods were performed
using either the R software package, v. 2.09 or Minitab,
v. 15.1.3.
Algorithm development and validation
Expression values for the 256 qRT-PCR genes were nor-
malized to the mean of ACLY and TFCP2, two low-
variability genes whose expression levels had previously
been observed to correlate with laboratory processing
effects. In a given sample, expression values for genes
were truncated if values exceeded the 0.01 and 0.99
quantile. A predictive model was fit and cross-validated
(10 fold, 1000 iterations) via forward stepwise logistic
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also patient age and sex. The binary response variable
(current/recent smokers vs. former and non-smokers) and
0.5 probability cut-point were prospectively defined for the
analysis of the validation set. The formula for the GES al-
gorithm is: (pr(Smoker)/(1-Pr(Smoker)) = 15.78306 +
0.3876 * SEX – 3.3368 * CLDND1-3.4034*LRRN3-1.4847 *
MUC1 + 5.9209 * GOPC + 2.27166 * LEF1 where SEX =1
if male, 0 if female.
Cotinine assay
Plasma cotinine levels were measured in 180 PREDICT
subjects using a commercially available ELISA assay
(Calbiotech, Spring Valley, CA), following the manufac-
turer's recommended procedure.
Results
Microarray identification of genes responsive to smoking
Whole genome microarray analysis was performed on
210 subjects of which self-reported smoking status was
available on 209. Forty-one of the subjects were current
smokers, 4 had recently quit (within 2 months), 64 were
former smokers (quit longer than 2 months) and 100
reported that they had never smoked; full demographics
are given in Table 1. Maximum coronary artery stenosis
(as defined by quantitative coronary angiography), age,
and neutrophil count were all significantly associated
with smoking status (Table 1). 5096 probes mapping to
4214 unique genes were significantly associated with
smoking status in a sex- and age-adjusted logistic regres-
sion model (p < 0.05, Additional file 1: Table S1); of the
4214 genes, 39% (1649) were down-regulated in
response to smoking status whereas 61% (2565) were
up-regulated. The most significant associations withTable 1 Clinical demographics of microarray subjects
Never Former
Variable* (N = 100) (N = 64)
Max QCA‡ 42.54±37 37.71±36
Sex (%Male) 67 (0.67) 54 (0.84)
Age (yrs) 59±13 63±11
Caucasian (%) 89 (0.89) 61 (0.95)
BMI 30±6 30±5
Systolic BP 136±18 133±18
Diastolic BP 83±12 79±12
Hypertension (%) 62 (0.62) 37 (0.578125)
Dyslipidemia (%) 63 (0.63) 36 (0.5625)
Neutrophil Count 3.9±1.2 3.8±1.3
Lymphocyte Count 1.9±0.5 1.9±0.7
*Mean values are given, ± SD or % in parenthesis.
† Variables with p values in bold are significantly different between the four catego
‡Maximum coronary artery stenosis in all major coronary vessels of a subject, as desmoking status were observed in two up-regulated genes
(LRRN3, CLDND1) both of which remained significant
after adjusting for multiple testing (p < 1.22 × 10-6).
To investigate associations of the 4214 genes with bio-
logical pathways and networks, the log-odds values from
the logistic regression model were used in a Gene Set
Enrichment Analysis (GSEA) [15]. This analysis however
did not yield any gene sets with a FDR of less than 0.25
(Additional file 1: Table S2). To further evaluate path-
ways and networks associated with the array genes, en-
richment of gene ontology terms was evaluated [11].
Two molecular function categories, 189 biological
process categories, and 60 cellular component categories
showed significant enrichment in a Bonferroni-corrected
analysis (corrected p value < 0.05, Additional file 1:
Table S3). The most significant categories included regu-
lation of apoptosis, cell death, regulation of immune sys-
tem process, and response to organic substance
(Figure 1A, B; p < 0.001).
To identify groups of correlated genes and subjects in
the microarray dataset, hierarchical clustering was per-
formed on the subjects and the subset of 227 genes
showing the most significant association with smoking
(p < 0.001, Figure 2). The subjects fell into two main
clusters, with 37 (90%) of the current smokers partition-
ing into one cluster (Figure 2). The genes also parti-
tioned into two main clusters; the larger cluster
consisting of genes up-regulated in response to smoking,
the smaller cluster containing down-regulated genes
(Figure 2, top and bottom cluster respectively). Cell
type-specific gene expression analysis of the clusters was
investigated using data from BioGPS, which was avail-
able for 172 of the genes (Additional file 1: Table S4)
[14]. The up-regulated cluster contained genes expressedRecent Current p value†
(N = 4) (N = 41)
47.3±44 57.13±37 0.029
3 (0.75) 34 (0.83) 0.063
53±14 54±11 0.006




2 (0.5) 20 (0.49) 0.180
2 (0.5) 23 (0.56) 0.308
4.8±1 4.8±1.7 < 0.001
2±0.2 2.1±0.7 0.063
ries (< 0.05).
termined by quantitative coronary angiography (QCA).
Figure 1 Gene ontology analysis of 4214 array genes associated with smoking. The 4214 smoking-associated genes were analyzed using
BINGO to identify significant biological processes. Significant processes (p < 0.001 after FDR correction) are colored with the gradient of p values
reflected in the colors as indicated, and the biological process annotated. (A) Cellular component ontological terms (B) Biological Process
ontological terms.
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(e.g. CLDND1, LRRN3, USP34) cells, whereas the down-
regulated cluster was enriched in genes expressed
strongly in hematopoietic-stem cells and early erythroid
cells (e.g. ALAS2, FECH, C5orf4, HEPB1).Validation of array genes responsive to smoking by qRT-
PCR
256 genes were selected from the microarray data based
on association with smoking or coronary artery disease
(CAD). The expression levels of the 256 genes were eval-
uated across 1071 PREDICT subjects, 201 (19%) of
which were self-reported smokers, 352 former smokers,
30 recently quit, and 488 subjects who had never
smoked. Of the 256 genes, 53% (135) showed a signifi-
cant association with smoking status in an age- and sex-
adjusted logistic regression model; 74% (59) of the 80
significant array genes remained significant by qRT-PCR
(Additional file 1: Table S5). Of this set, all but 3
(HIST1H2AC, NONO, PAPD4) agreed with the array
data in directionality of gene expression. LRRN3
remained the gene most significantly associated with
smoking status, followed by CLDND1, SASH1, and
P2RY6 (p < 0.001, Figure 3).Gene expression model development and validation
Step-wise forward logistic regression was utilized to con-
struct a gene-expression model predictive of self-
reported smoking status; smoking status was used as the
dependent variable, with age, sex and the expression
levels of the 256 genes used as independent variables.
The model selected five genes (LRRN3, CLDND1,
MUC1, GOPC, LEF1); in a cross-validated assessment of
model performance in which current and recently quit
smokers were combined into one group, and former and
never-have-smoked subjects into a second, the model
had an AUC of 0.93 (Table 2, Additional file 2: Figure
S1A), with a sensitivity of 0.79 and a specificity of 0.95
(cutoff = 50% probability of smoking, Table 2). Model
performance was validated using 180 independent PRE-
DICT subjects, with an AUC of 0.82 (95% CI 0.65-0.94),
a sensitivity of 0.63 and a specificity of 0.94 (Table 2,
Additional file 2: Figure S1B).
Comparison of gene expression model performance to
cotinine
The level of cotinine, a nicotine metabolite commonly
used to determine smoking status, was assessed by ELISA
assay across the 180 validation subjects [16]. Using a pre-
specified threshold of 10 ng/ml, cotinine levels provided
Figure 2 Hierarchical clustering of 209 subjects and 227 array genes associated with smoking (p < 0.001). The dendogram on top shows
correlations between subjects; black bars at bottom denote current smokers; red bars denote recently quit smokers. Dendogram on the left
shows correlations between genes; positions of representative cell-specific genes are shown on the right.
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and a specificity of 0.97 (Table 2, Additional file 2:
Figure S1C). Moderate concordance was observed be-
tween the gene expression model and cotinine (91%
agreement, 95% CI 85.97-94.83, kappa = 0.53; Figure 4);
where both methods reported positive smoking status,
85% (11) subjects were self-reported smokers, 1 had re-
cently quit, and 1 was a former smoker (Figure 4, upper
right quadrant).
Discussion
This study presents gene discovery from microarrays
and the development and validation from a large qRT-
PCR data set of a whole blood-derived, qRT-PCR based
gene expression score for the assessment of smoking sta-
tus. The initial microarray analysis identified 4214
genes associated with self-reported smoking status. A
number of biological pathways known to be affected by
smoking showed GO enrichment within this set of genes,
including apoptosis and cellular death, immune system
development, leukocyte activation, hemopoiesis, stressresponse, and alterations in platelet activity (Additional
file 1: Table S3) [11]. When clustered, the most significant
array genes partitioned into two main groups, which
appeared to be partially driven by cell-type expression
(Figure 3); notably most of the down-regulated genes
appeared to be predominantly expressed in CD71+ and
CD105+ cell types (Additional file 1: Table S4).
The majority of the genes selected to be analyzed by
qRT-PCR (53%) showed a significant association with
smoking. Expression levels of the most significant genes
(e.g. LRRN3, CLDND1) were roughly equivalent in former
smokers and subjects that had never smoked; likewise
recently quit smokers appeared more like current
smokers (Figure 3). In former smokers gene expres-
sion decreased with time elapsed since smoking cessa-
tion, however it did not reach non-smoker levels,
suggesting that although the impact of smoking on
gene expression diminishes over time, it may never
be completed resolved (Figure 3). Alternatively, there
may be a genetic effect on gene expression levels for genes
that are associated with the ability to stop smoking.
Figure 3 Expression levels of four most significant genes as assessed by qRT-PCR across 1074 PREDICT subjects grouped by self-
reported smoking status. Expression levels are shown in Cp units on the Y axis, self-reported smoking status is shown on the X axis. (A) LRRN3;
(B) CLDND1; (C) SASH1; (D) P2RY6.
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sociate these two possibilities.
The performance of the gene expression model
remained fairly consistent across both the development
set and validation sets, with a lower AUC seen in the
validation set (Table 2). In both sets of subjects the
expression model showed higher specificity and negative
predictive value (NPV) versus sensitivity and positive
predictive value (PPV). The use of cotinine levels to
classify subjects provided a better AUC (Table 2), show-
ing moderate concordance with the gene expression
model (91% agreement, 95% CI 85.97-94.83; kappa = 0.53,Table 2 Performance of GES and cotinine models
AUC* Sensitivity Specificity
GES – Development Set 0.93 0.79 0.95
GES – Validation Set 0.82 (0.65-0.94) 0.63 0.94
Cotinine – Validation Set 0.89 (0.81-0.97) 0.81 0.97
*95% confidence interval is shown in parentheses. As the AUC for the
development set was derived via cross-validation, a confidence interval could
not be assigned. However, the standard deviation of the cross-validation runs
equaled 0.03; the standard error equaled 0.001.p < 0.001, Figure 4). Interestingly, both methods pro-
duced independent sets of false positives (4 subjects by
cotinine, 9 by GES; top left and bottom right quadrants,
Figure 4). Levels of cotinine are elevated in passive
smokers, and it is likely that gene expression may also
be sensitive to second-hand smoke or other environ-
mental factors [16,17].
This study had a number of limitations. Self-reported
smoking status is an imperfect gold-standard as subjects
may not report their status correctly. The number of
subjects in certain groups (e.g. recently quit) was limit-
ing; larger numbers might have allowed for identification
of better classifiers. A strong CD105+/CD71+ signature
was seen in the microarray data, and although genes
associated with this array signature were assessed by
qRT-PCR (e.g. C5orf4), they were not chosen during
model development; it is possible that other candidates
from this group could add to algorithm performance.
Clinical data relating to some aspects of smoking status
was limited; lack of details regarding packs per day or
date of smoking cessation prevented identification of
subtler changes in gene expression in response to
Figure 4 Comparison of gene expression score to cotinine levels in validation set. The y-axis shows the log10 value of cotinine levels in
the 180 subject validation set; the horizontal dashed line (−−-) denotes the 10ng/ml threshold used in the AUC analysis. The x-axis shows the
GES in the 180 subject validation set; the vertical dashed line denotes the 50% probability threshold used in the AUC analysis. Black circles = non-
smokers; red circles = former smokers (> 2 months quit); green circles = recently quit smokers (< 2 months quit); blue circles = current smokers.
All smoking categories are self-reported.
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ure prevented assessment of this contribution to changes
in gene expression. Finally, this study was not designed
to assess whether the observed changes in gene expres-
sion were a result of direct exposure of circulating cells
to toxins, or due to interactions with damaged lung
tissue.
A GES for the determination of smoking status has
limited clinical value per se, as self-reported smoking
status is fairly reliable. One of the main goals of this
study was to identify gene expression changes that cor-
relate with smoking in the hope of understanding the
underlying biology of smoking-related diseases. This has
been previously done by examining changes in the ex-
pression levels of individual genes; the development of a
GES however allows for easier comparison to other
methods (e.g. cotinine), providing an assessment of the
accuracy of gene expression as a marker for smoking
[18,19]. In addition, a GES also provides an avenue to
assess expression changes in other pulmonary disease
cohorts in relation to what is observed with smoking,
and may also be useful in examining populations
exposed to airborne pollutants.
The biology associated with the genes in the final ex-
pression model is intriguing. LRRN3 which encodes a
leucine-rich repeat protein, and CLDN1, a claudin-
domain containing gene, are both highly expressed in lym-
phocytes and were previously identified by Charlesworth
et al. who used microarrays to examine changes in
lymphocyte gene expression in response to smoking [18].
Interestingly, CLDND1 is also up-regulated in lungsquamous cell carcinomas [20]. MUC1 encodes a
membrane-bound protein that is a member of the mucin
family; increases in MUC1 protein levels are associated
with poor prognosis of non–small cell lung cancer [21].
GOPC, a coiled-coil motif and PDZ containing protein,
negatively regulates CFTR, mutations in which result in
cystic fibrosis [22]. Finally, LEF1 is a transcriptional en-
hancer also highly expressed in lymphocyte cells and is
involved in the Wnt signaling pathway [23].
It is interesting to speculate on the relation between
the observed changes in gene expression and the devel-
opment of smoking-associated diseases. Expression
levels of CLDND1 remain significantly associated with
the presence of CAD in a multivariable model adjusting
for smoking status as well as age and sex (unpublished
observation); it remains to be determined whether these
changes are causal or merely reflective. Likewise,
changes in the expression levels of both CLDND1 and
MUC1 are associated with the development of lung can-
cer; it would be interesting to assess the performance of
the gene expression model in subjects with other
smoking-related diseases such as lung cancer, asthma,
and COPD. The validation set contained a number of
subjects with false positive and false negative results
assigned by both the gene expression model and coti-
nine; it would be interesting to study whether disease
risk was altered in such patients.
Conclusion
Using microarray and qRT-PCR data sets, comprising
over 1000 patients, we have investigated the relationship
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smoking status and derived a gene-expression based al-
gorithm consisting of 5 genes which can accurately as-
sign smoking status to patients. While others have
reported the effect of smoking on gene expression in
lymphocytes and monocyte-derived macrophages, to our
knowledge the current study is the first to look at such
changes in RNA isolated from whole blood and to derive
a predictive GES [18,19]. Further investigation into the
biology behind the genes identified in this study may
shed additional light on the relationship between smok-
ing and increased cardiovascular disease risk, and assess-
ment of the performance of the expression model in
patients with other smoking-related disorders such as
asthma, COPD, and lung cancer might lead to new diag-
nostic methods for these conditions.
Additional files
Additional file 1: Table S1. The 5096 microarray features significantly
associated with smoking status (sex- and age-adjusted logistic regression
model, p < 0.05). Table S2. Biological pathways and networks identified
through Gene Set Enrichment Analysis associated with significant
microarray genes. Table S3. Gene ontology terms associated with
significant microarray genes (Bonferroni-corrected, p < 0.05). Table S4.
Cell type-specific gene expression of most significant microarray genes
(p < 0.001). Table S5. The 256 genes evaluated by qRT-PCR; p values and
coefficients are shown for association with smoking status.
Additional file 2: Figure S1. ROC analysis of gene expression score
(GES) and cotinine.
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